Cognitive Neurology Unit Clinical Registry

Summary

A Prospective Comparative Study Of Monoclonal Antibodies For The Treatment Of Alzheimer's Disease

Eligibility

Inclusion Criteria:

* o Patient meets clinical criteria for mild cognitive impairment or early dementia from Alzheimer's disease

  * Patient has evidence of cognitive impairment on neuropsychological testing
  * Patient has not progressed to the moderate stage of dementia based on neuropsychological testing or clinical judgement
  * Amyloid PET imaging and/or CSF analysis consistent with Alzheimer's disease
  * Amyloid PET imaging positive
  * CSF p-Tau/Abeta42 ration \>0.023 and ABeta42 \< 1027\*\*
  * 3T MRI in past 6 months
  * Patient has a care partner
  * Patient under the care of an appropriate BI-Lahey amyloid clinic
  * Patient is on a stable medication regimen

Exclusion Criteria:

* o Recent stroke or suspected TIA in the past year

  * Pregnancy
  * Active autoimmune or immunological disease
  * Systemic treatment with immunosuppressants, immunoglobulins, or monoclonal antibodies or their derivatives
  * Bleeding disorder with Plts \< 50,000 or INR \> 1.5
  * On warfarin, heparin, or DOAC
  * On dual antiplatelet therapy
  * Non Alzheimer disease cause of dementia/MCI
  * ApoE e4 homozygote

Conditions2

Locations1 site

Browse More Trials